Precision Biosciences Highlights Progress On 2 Strategies Designed To Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma
Company Reports Updated Phase 1/2a Interim Study Results for 12 R/R Non-Hodgkin Lymphoma Patients who Received PBCAR0191 CAR T Cells Following Enhanced Lymphodepletion (eLD)
- Median Interval of 1 Day from Enrollment to
Precision BioSciences’ CD-19 CAR T Therapy Shows Response Rate Of 77% In Lymphoma Trial
Precision BioSciences Inc (NASDAQ: DTIL) announced additional data from its Phase 1/2a study evaluating PBCAR0191, off-the-shelf, allogeneic CAR T candidate targeting…
Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021
Cullinan Oncology (CGEM) - https://www.globenewswire.com/news-release/2021/05/19/2232874/0/en/Cullinan-Oncology-to-Provide-CLN-081-Clinical-Update-at-ASCO-2021.html
BeiGene (BGNE)
Earnings Scheduled For May 13, 2021
Companies Reporting Before The Bell
• CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.
Why Precision BioSciences Stock Is Trading Higher Today
Precision BioSciences (NASDAQ: DTIL) shares are trading higher after the company reported its ARCUS platform showed a promising gene editing approach for transthyretin amyloidosis.
Precision Biosciences US Patent & Trademark Office Abstract ‘OPTIMIZED ENGINEERED NUCLEASES HAVING SPECIFICITY FOR THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE’
http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220210113616%22.PGNR.&OS=DN/20210113616&RS=DN/2021
98 Biotechnology Stocks Moving In Wednesday’s Session
Gainers • Neurotrope, Inc. (NASDAQ:NTRP) stock increased by 131.7% to $3.36 during Wednesday’s regular session. • Genprex, Inc.…
116 Healthcare Stocks Moving In Wednesday’s Session
Gainers • Neurotrope, Inc. (NASDAQ:NTRP) stock moved upwards by 133.1% to $3.38 during Wednesday’s regular session. • Genprex,…